# MoonLake Immunotherapeutics submits sonelokimab BLA — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/ec3c608dc162827f

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-09-30 21:48 ingested 2026-10-01 03:03

[original source ↗](https://seekingalpha.com/news/4648802-moonlake-immunotherapeutics-submits-sonelokimab-bla?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

MoonLake Immunotherapeutics submits sonelokimab BLA

Sep 30, 2026, 5:48 PM ETMoonLake Immunotherapeutics (MLTX) StockUCBJFBy : Jonathan Block, SA News Editor

MoonLake Immunotherapeutics (MLTX) submitted a BLA to the US FDA seeking approval of sonelokimab for hidradenitis suppurativa.

The company has completed two phase 3 studies, VELA-1 and VELA-2, of the tri-specific nanobody in adults. It also has the phase 3 VELA-TEEN

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You
```



document fetched 2026-10-01 03:03 · canonical https://seekingalpha.com/news/4648802-moonlake-immunotherapeutics-submits-sonelokimab-bla?feed_item_type=news